CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2

CHUNLING ZHAO1*, SHUXIAN ZHENG2*, ZIQIAN YAN2, ZIKUN DENG2, RUIGE WANG2 and BAOGANG ZHANG2

Departments of 1Cell Biology and 2Pathology, Weifang Medical University, Weifang, Shandong 261053, P.R. China

Received November 16, 2018; Accepted August 23, 2019

DOI: 10.3892/or.2019.7426

Abstract. Chemokine (C-C motif) ligand 18 (CCL18) is derived from breast tumor-associated macrophages (TAMs), which are primarily a macrophage subpopulation with an M2 phenotype. CCL18 binds to its receptor, PYK2 N-terminal domain interacting receptor 1 (Nir1), and promotes tumor progression and metastasis by inducing epithelial-mesenchymal transition (EMT) via the PI3K/Akt/GSK3β/Snail signaling pathway in breast cancer cells. Recent research shows that Annexin A2 (AnxA2) plays a significant role in the invasion, metastasis, angiogenesis, proliferation, F-actin polymerization and multidrug resistance to chemotherapy of breast cancer. The present study aimed to elucidate the molecular mechanisms by which CCL18 promotes breast cancer progression through AnxA2 which are not fully understood. Western blot analysis showed that the expression of AnxA2 was upregulated in highly invasive breast cancer cell lines and invasive ductal carcinoma. Furthermore, through chemotaxis, scratch, Matrigel invasion, and spontaneous metastasis assays, it was demonstrated that AnxA2 enhanced the invasion of breast cancer cells and the metastasis of human breast cancer cells to lungs of SCID mice with CCL18 stimulation. Cellular F-actin measurement assay showed that reduction of AnxA2 suppressed CCL18-induced F-actin polymerization though phosphorylation of integrin β1 in breast cancer cells. Immunofluorescence and western blot analysis revealed that AnxA2 promoted CCL18-induced EMT via the PI3K/Akt/GSK3β/Snail signaling pathway, and LY294002 inhibited the phosphorylation of AnxA2 in vitro. In brief, AnxA2, as a downstream molecule of Nir1 binding to CCL18, promotes invasion and metastasis by EMT through the PI3K/Akt/GSK3β/Snail signaling pathway in breast cancer. This study suggests that AnxA2 is a potential anti-invasion/metastasis target for therapeutic intervention in breast cancer.

Introduction

Breast cancer is the most commonly diagnosed malignant tumor in women worldwide. Despite the numerous and advanced types of combined therapy, breast cancer remains among the main causes of tumor-related deaths in women (1). Breast cancer is associated with aggressive local invasion, metastasis in advanced stage and multidrug resistance to chemotherapy (2). Various molecular markers have been identified that contribute to the regulation of breast cancer invasion and metastasis, such as cell cycle regulators and cell-adhesion proteins (3).

The binding of chemokines to specific G-protein-coupled receptors induce cytoskeletal rearrangement and directional migration and then critically regulate tumor cell migration and metastasis (4). Chemokines were initially characterized due to their association with inflammatory responses. These are members of a superfamily of chemotactic cytokines (5). Chemokine (C-C motif) ligand 18 (CCL18) is a type of chemokine, which is predominantly derived from breast tumor-associated macrophages (TAMs) (6). Previous data indicate that the binding of CCL18 to its receptor, PYK2 N-terminal domain interacting receptor 1 (Nir1), promotes the invasion, metastasis and EMT of breast cancer cells through the PI3K/Akt/GSK3β/Snail signaling pathway (3,7). However, the involvement of other factors in the CCL18-induced migration, invasion and metastasis of breast cancer cells remains unclear.

AnnexinA2 (AnxA2), a member of the calcium-dependent phospholipid binding proteins, plays a crucial role in cancer progression (8,9). AnxA2 is reported to be overexpressed in a variety of cancers and contributes to invasion (10-12), metastasis (11,13), angiogenesis (14), proliferation (13,15-17), F-actin polymerization (16), multidrug resistance to chemotherapy (18-20) and epithelial-mesenchymal transition (EMT) (9).

EMT is crucial in embryonic development and cancer progression and it is a process during which epithelial-like cancer cells transform into mesenchymal-like tumor cells with upregulation of mesenchymal markers and downregulation of epithelial markers. Moreover, EMT is a vital contributor...
to the invasion and metastasis of breast cancer cells (21,22). In the present study, we detected the association of AnxA2 expression in breast tissue specimens with the clinicopathological characteristics of patients and observed the role of AnxA2 expression in breast cancer migration and invasion under the induction of rCCL18 to verify the hypothesis that AnxA2 promotes CCL18-induced progression and metastasis of breast cancer cells. In our research, AnxA2 was found to contribute to CCL18-induced phosphorylation of integrin β1 in breast cancer cells, which is a crucial step in cytoskeletal rearrangement and cell adhesion.

We hypothesized that the binding of CCL18 to Nir1 promotes tumor progression and metastasis by inducing EMT via the PI3K/Akt/GSK3β/Snail signaling pathway though AnxA2 in vitro and in vivo.

Materials and methods

Patients and tissue specimens. All tissue specimens were obtained from the Department of Pathology, Affiliated Hospital of Weifang Medical University from 1 January 2012 to 31 December 2016. These tissue specimens consisted of samples from 120 cases of invasive ductal carcinoma and their corresponding adjacent non-tumor tissues. The distance between invasive ductal carcinoma and their corresponding adjacent non-tumor tissues was >5 cm. The mean age of the patients was 47.3 years (range, 35-76). All tissue specimens were fixed, embedded in paraffin, serial sectioned and H&E stained and finally stored at room temperature. The inclusion criteria for the patients was a diagnosis of breast cancer and agreement to participate in the present study. Patient samples were collected according to a protocol approved by the Institutional Review Board, and patients provided signed consent for use of their tissue specimens in the present study. The study protocol was reviewed and approved by the Weifang Medical University Ethics Committee (approval no. 045, 26-Feb-2016). Clinical information of the samples is documented in detail in Table I.

Cell lines and reagents. The human breast cancer cell lines, MDA-MB-231, T47D and MCF-7, were obtained from the American Type Culture Collection (ATCC). Lipofectamine 2000 was obtained from Invitrogen; Thermo Fisher Scientific, Inc. Plasmid construction was carried out by Genescript (USA). The PierceTM BCA Protein Assay Kit and the PierceTM ECL kit were purchased from Thermo Fisher Scientific, Inc. Primary antibodies including anti-AnxA2 (dilution 1:1,000; cat. no. ab178677; Abcam), anti-phospho-AnxA2 (1:1,000; cat. no. sc-135753; Santa Cruz Biotechnology), anti-Akt (dilution 1:1,000; cat. no. 2920; Cell Signaling Technology), anti-phospho-Akt-Ser473 (dilution 1:1,000; cat. no. 15116; Cell Signaling Technology), anti-phospho-Akt-Thr308 (dilution 1:1,000; cat. no. 13038; Cell Signaling Technology), anti-integrin β1 (dilution 1:1,000; cat. no. 34971; Cell Signaling Technology), anti-phospho-integrin β1 (dilution 1:1,000; cat. no. 44–873G; Thermo Fisher Scientific, Inc.), anti-GSK3β (dilution 1:1,000; cat. no. 12456; Cell Signaling Technology), anti-phospho-GSK3β (dilution 1:1,000; cat. no. 9323; Cell Signaling Technology), anti-E-cadherin (dilution 1:1,000; cat. no. 7687; Cell Signaling Technology), anti-N-cadherin (dilution 1:1,000; cat. no. 13116; Cell Signaling Technology), anti-vimentin (dilution 1:1,000; cat. no. 3390; Cell Signaling Technology), anti-Snail (1:1,000; cat. no. 3895; Cell Signaling Technology), β-actin (dilution 1:1,000; cat. no. 3700; Santa Cruz Biotechnology), anti-Nucleolin (dilution 1:1,000; cat. no. ab22758; Abcam) and the anti-mouse, rabbit and goat secondary antibodies were obtained from Santa Cruz Biotechnology, Inc. Fluorochrome-conjugated secondary antibodies, Alexa Flour 594 and TRITC, (Invitrogen; Thermo Fisher Scientific, Inc.) were diluted 1:600 in blocking buffer (Solarbio). All culture media and related reagents were purchased from Hyclone/GE Healthcare, USA.

Animals. Forty 1-week-old female SCID mice were purchased from Wei Tong Li Hua Experimental Animal Co. (initial mean weight 18.3 g; range 16.3-19.7 g). The mice were maintained in laminar flow rooms under constant temperature and humidity. The food and water of mice were sterilized, and the food and water were renewed ad libitum.

Plasmid construction, shRNA and plasmid transfection. Cells were cultured in a 6-well plate for 24 h in complete medium before transfection. Transfection was performed with Lipofectamine 2000 according to the manufacturer’s instructions. Sequences of AnxA2 siRNA were 5’-GGTCTG AATTCCAAGAGAA-3’ and 5’-GCCAAGAAATGAGAc ATTC-3’. Sequences of Nir 1 siRNA were 5’-GGGAGA AGUGGGCUUCGUATATT-3’ and 5’-UUACGAGAGCACCU UCUCCCGG-3’. Sequences of Akt siRNA were 5’-GCC GGCUCCACAACGUUGUGAAUA-3’ and 5’-UUAUCAC CCACGUUGUGACCCGC-3’. Culture medium with 600 ng/ml hygromycin B was used to select stably transfected cells. The MDA-MB-231 cells were stably transfected with the sequences of AnxA2 siRNA, Nir 1 siRNA or Akt siRNA respectively marked as SiAnxA2/MDA-231, SiNir1/MDA-231 and SiAkt/MDA-231. A scrambled SiRNA was used as a control (Scr/MDA-231). Surviving cells were evaluated for AnxA2 expression by western blot analysis. For plasmid transfection, cells were plated in a 6-well plate for 24 h before transfection. AnxA2 cDNA was cloned in the KpnI-XbaI sites of pcDNA3.1, and was confirmed by DNA sequencing. MCF-7 cells were transfected with the pcDNA3.1-AnxA2 plasmid, pcDNA3.1-Nir1 plasmid, pcDNA3.1-Akt plasmid or pcDNA3.1 vector using Lipofectamine 2000 and marked as AnxA2/MCF-7, Nir1/MCF-7, Akt/MCF-7 or Con/MCF-7. Stable transfected cells were selected and maintained in culture medium with G418.

Western blot analysis. Total cellular proteins were extracted with ice-cold RIPA cell lysis buffer with Protease Inhibitor Cocktail. We employed the BCA Protein Assay Kit (Pierce) to quantify the protein concentration. The amount of protein loaded in each lane is 10 µl. Lysates were separated by 10% SDS-PAGE and transferred onto a PVDF membrane. The membrane was incubated in primary antibodies, horseradish HRP-conjugated anti-rabbit IgG secondary antibody successively. Western blots were visualized using an ECL kit (Pierce; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. β-actin was served as an internal loading control for each blot. The intensity of the detected bands was analyzed using an ImageJ software (version 1.42; National Institutes of Health).
Table I. Association between AnxA2 expression and clinical features of the invasive ductal carcinoma patients enrolled in this study.

<table>
<thead>
<tr>
<th>Variables</th>
<th>AnxA2 expression</th>
<th></th>
<th></th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>High 34</td>
<td>Low 19</td>
<td></td>
<td>0.190</td>
</tr>
<tr>
<td>≥51</td>
<td>High 35</td>
<td>Low 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5 cm</td>
<td>High 31</td>
<td>Low 23</td>
<td></td>
<td>0.723</td>
</tr>
<tr>
<td>&gt;5 cm</td>
<td>High 40</td>
<td>Low 26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor differentiation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>High 17</td>
<td>Low 21</td>
<td></td>
<td>0.036</td>
</tr>
<tr>
<td>II</td>
<td>High 25</td>
<td>Low 16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>High 30</td>
<td>Low 11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>High 48</td>
<td>Low 21</td>
<td></td>
<td>0.007</td>
</tr>
<tr>
<td>No</td>
<td>High 23</td>
<td>Low 28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>High 46</td>
<td>Low 20</td>
<td></td>
<td>0.009</td>
</tr>
<tr>
<td>No</td>
<td>High 25</td>
<td>Low 29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nir1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>High 55</td>
<td>Low 24</td>
<td></td>
<td>0.006</td>
</tr>
<tr>
<td>Negative</td>
<td>High 18</td>
<td>Low 23</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AnxA2, annexin A2. P-values in bold print indicate statistically significant results.

Wound healing/scratch assay. Wound healing/scratch assays were carried out as previously described (23). In brief, cells were plated in 6-well plates and cultured to a monolayer. Next, a scratch was created in the middle using a 10-µl pipette tip. The medium was replaced by 1% bovine serum albumin (BSA) in RPMI medium. The cells were incubated at 37°C in a sterile incubator, and the wound trace was photographed at 0, 5, 10, 15 and 20 h. The distance of the scratch (in mm) was measured under a light microscope at magnification x200. All samples were examined in triplicate, and the data are shown as the means.

Chemotaxis assay. Chemotaxis assay was performed as described previously (3,23). Briefly, a polycarbonate filter membrane was inserted between the upper and lower chambers. After pretreatment with 10 µg/ml fibronectin overnight, it was dried in air. CCL18, as chemoattractant, was added into the lower chamber and the cell suspension at a final concentration of 5x10⁶/ml was added to the upper chambers. Then, the chamber was incubated at 37°C in a sterile incubator for 3 h. The filter membrane was washed, fixed and stained. The number of migrating cells was calculated using a microscope at a magnification x400 in three random fields. Chemotaxis index=the number of migrating cells in the chemoattractant gradient/the number of migrating cells in the medium control. All samples were tested in triplicate and the data are shown as the means.

Adhesion assay. The adhesion assays was conducted as previously described (23). The cells suspension at a final concentration of 3x10⁶/ml incubated at 37°C in a sterile incubator for 20 min, and then, cells were promptly added to a 24-well plate containing dried glass coverslips with or without 10 ng/ml rCCL18. The coverslips were pretreated with fibronectin and then dried for 30 min. After 5, 15 and 30 min of incubation, the cells were washed and fixed. The number of cells attached to the coverslips were calculated using a light microscope at magnification of x400.

Cellular F-actin measurement. F-actin polymerization assay was performed as previously described (4,24). In brief, cells were cultured for 24 h in complete medium and cultured in binding medium for 2 h. Cells were fixed, permeabilized, and stained in the dark with TRITC-labelled Phalloidin, which was diluted in F-buffer (10 mM HEPES, 20 mM KH₂PO₄, 5 mM EGTA, 2 mM MgCl₂, Dulbecco's PBS, pH 6.8) for 30 min. Cells was measured by fluorescence analysis. The F-actin content was calculated by the following equation: F-actin Δt/F-actin 0=(fluorescence Δt/mg per ml/fluorescence 0/mg per ml). All experiments were repeated at least three times.

Immunofluorescence. Immunofluorescence was performed as previously described (3). Briefly, the cells were cultured in 24-well plates containing sterile coverslips 24 h before this experiment, and then starved overnight. After stimulation with 10 ng/ml rCCL18, cells were washed, fixed and permeabilized as previously described (3). Cells were incubated in primary antibody overnight at 4°C. Negative control comprised rabbit IgG. The cells were then directly incubated at room temperature for 2 h in dark with Alexa Fluor 594-conjugated secondary antibodies and 4”,6-diamidino-2-phenylindole (DAPI) in the dark. The results were analyzed using fluorescence microscopy. All experiments were repeated at least three times.

In vivo spontaneous metastasis assay. Metastasis assays were performed as described previously (3). Forty SCID mice were randomly divided into four groups. In total, the Scr/MDA-231 or SiAnxa2/MDA-231 cell suspension at a final concentration of 2x10⁶/ml was injected into the mammary fat pads of the mice. When the xenografts were 0.5 cm in diameter, an intratumoral injection of 100 ng/kg rCCL18 or the same volume of vehicle was administered biweekly for 4 continuous
weeks. After 8 weeks, the mice were sacrificed by cervical dislocation, and the lung surface nodules were counted. The lung tissues were fixed, embedded in paraffin, serial sectioned and H&E stained to detect lung micrometastasis. The study protocol for the animal study was reviewed and approved by Weifang Medical University Ethics Committee (approval no. 045, 26-Feb-2016).

Results

Expression of AnxA2 in breast cancer and the correlation between AnxA2 and clinicopathological characteristics of the breast cancer cases. Comparative evaluation was carried out of the AnxA2 expression of the paired invasive ductal carcinoma tissues and adjacent non-tumor tissues by western blot analysis. The coupled tissues were obtained from the same patient. Our results showed that the protein level of AnxA2 was overexpressed in invasive ductal carcinoma tissues when compared with that in the coupled adjacent non-tumor tissues (Fig. 1A, left image). To further investigate the correlation between AnxA2 and the clinicopathological characteristics of the breast cancer cases, we assessed the expression of AnxA2 in 120 archived paraffin-embedded specimens of invasive ductal carcinoma and the coupled adjacent non-tumor tissues by qRT-PCR. Our experimental results indicated that the expression of AnxA2 in the invasive ductal carcinoma tissues was significantly associated with tumor differentiation, lymphatic metastasis, distant metastasis and Nir1 expression, but it was independent of age and tumor size (Table I).

As our results showed that the protein level of AnxA2 was overexpressed in invasive ductal carcinoma tissues compared with that in the coupled adjacent non-tumor tissues, we assessed the AnxA2 level in breast cancer cell lines. The protein level of AnxA2 was diverse in the breast cancer cell lines. Highly invasive cells (MDA-MB-231) expressed a higher level of AnxA2 than the low-invasive cells (T47D and MCF-7) (Fig. 1A, right image). Furthermore, CCL18 affected the phosphorylation levels of AnxA2 in breast cancer cells in a time-dependent manner, but not the expression of AnxA2 in MCF-7 and MDA-MB-231 cells (Fig. 1B).

AnxA2 contributes to CCL18-induced chemotaxis in breast cancer cells. We used siRNA to inhibit Nir1 or AnxA2 expression to determine the specific function of AnxA2 breast cancer cells. Tygromycin B was used for selecting the successfully transfected cells that stably downregulated the expression of Nir1 or AnxA2. SiRNAs (SiAnxA2#1 and SiAnxA2#2) were designed to target Nir1 or AnxA2. Scr/MDA-231 cells were used as control cells that were transfected with a scrambled sequence. We chose SiNir1/MDA-231 and SiAnxA2/MDA-231 cells as the representatives.

Simultaneously, AnxA2 or Nir1 stably transfected cell clones were generated by pcDNA3.1-AnxA2 or pcDNA3.1-Nir1 plasmid subsequent selection. Stable transfected cells were obtained by using medium (culture medium with 600 ml G418). Hence, we decided to present the results from clone 4, designated as AnxA2/MCF-7 and Nir1/MCF-7 cells. Con/MCF-7 cells were used as vector control cells that were transfected with a pcDNA3.1 vector. We performed western blot analysis to identify the protein and phosphorylation levels of AnxA2 in Scr/MDA-231, SiNir1/MDA-231, Con/MCF-7, and Nir1/MCF-7 cells with or without rCCL18 stimulation. Our results indicated that the expression of Nir1 affected CCL18-induced AnxA2 phosphorylation. In other words, CCL18 binding to Nir1 promoted the phosphorylation levels of AnxA2 in breast cancer cells, but not the expression of AnxA2 (Fig. 1C). We performed western blot analysis to identify AnxA2 in stably transfected cell clones. The results are illustrated in Fig. 1D and F. We performed chemotaxis assay to determine whether AnxA2 contributed to CCL18-induced breast cancer cell chemotaxis. The CCL18-induced chemotaxis ability of the diverse breast cancer cell lines followed a representative bell-shaped response curve (Fig. 1E and G). These chemotaxis assay results indicated that AnxA2 promotes CCL18-induced chemotaxis in breast cancer cells.

Decrease in AnxA2 suppresses adhesion, migration and invasion in breast cancer cells. Migration, invasion and proliferation are correlated with a highly aggressive phenotype in breast cancer. Previous studies (9,17,18,25,26) suggest that AnxA2 promotes invasion, migration, proliferation and adhesion in cancer cells. Moreover, chemokine-induced adhesion contributes to cell movement (26). We aimed to determine the influence of AnxA2 on the adhesion in breast cancer cells with or without CCL18 stimulation. Our results revealed that treatment with 10 ng/ml of rCCL18 promoted the adhesion, which was significantly impaired in the SiAnxA2/MDA-231 cells (Fig. 2A). The results indicated that AnxA2 promoted CCL18-induced cell adhesion. To identify whether AnxA2 affects CCL18-induced migration and invasion in breast cancer cells, we carried out scratch assays and Transwell invasion assays. When a wound was created in the cells, the distance of the SiAnxA2/MDA-231 and Scr/MDA-231 cells were transfected with a pcDNA3.1 vector. We performed western blot analysis to identify the protein and phosphorylation levels of AnxA2 in stably transfected cell clones. The results are illustrated in Fig. 2B. The number of SiAnxA2/MDA-231 cells that invaded the Matrigel were considerably fewer than the Scr/MDA-231 cells with or without rCCL18 stimulation (Fig. 2B). The number of SiAnxA2/MDA-231 cells that invaded the Matrigel were considerably fewer than the Scr/MDA-231 cells with or without rCCL18 stimulation (Fig. 2B). The number of SiAnxA2/MDA-231 cells that invaded the Matrigel were considerably fewer than the Scr/MDA-231 cells after 24 h, and there was no obvious difference in the invasion between SiAnxA2/MDA-231 and Scr/MDA-231 cells without rCCL18 stimulation after 24 h. These results showed that suppression of AnxA2 inhibited CCL18-induced adhesion, migration and invasion in breast cancer cells.

Reduction in AnxA2 suppresses CCL18-induced F-actin polymerization in breast cancer cells. The migration and chemotaxis of cells depend on the actin-based cytoskeleton (27,28). The process of F-actin polymerization is quick and transient (29). To testify the hypothesis that the downregulation of AnxA2 could suppress CCL18-induced chemotaxis
of breast cancer cells by suppressing F-actin polymerization, we performed F-actin polymerization assay. The results indicated that CCL18 elicited transient actin polymerization at 15 and 60 min in the Scr/MDA-231 cells. Actin polymerization was significantly decreased in the SiAnxA2/MDA-231 cells (Fig. 3A), which suggested that AnxA2 plays a vital role in regulating cytoskeleton rearrangement with CCL18 stimulation. Immunofluorescent staining was used to detect the F-actin content. rCCL18 increased the F-actin content in the Scr/MDA-231 cells, but not in SiAnxA2/MDA-231 cells.
Integrin β1 binding to fibronectin plays a crucial part in adhesion of breast cancer cells (30). Thus, western blot analysis was performed to detect the CCL18-induced activation of integrin β1. As shown in Fig. 3C, the CCL18-induced phosphorylation of integrin β1 was distinctly impaired in the SiAnxA2/MDA-231 cells, in accordance with a reduction in adhesion. The results indicated that AnxA2 regulated migration and invasion directly by modulating the CCL18-induced adhesion and F-actin polymerization in the MDA-MB-231 cells.

AnxA2 promotes CCL18-induced EMT via the Akt/GSK3β signaling pathway. EMT is a well-coordinated process during cancer progression, which is related to the metastatic potential of tumor cells. Our previous study (3) indicated that CCL18 binding to Nir1 enhances the invasion ability of breast cancer cells through the PI3K/Akt/GSK3β/Snail signaling pathway. We assumed that AnxA2, as the downstream molecule of CCL18 that binds to Nir1, promotes progression and metastasis by EMT of breast cancer cells through the PI3K/Akt/GSK3β/Snail signaling pathway in breast cancer cells. To investigate the role of AnxA2 in the promotion of migration and metastasis in breast cancer cells through EMT, we performed western blot assays and immunofluorescence to detect vimentin, N-cadherin (mesenchymal marker), and E-cadherin (epithelial marker) in cells with or without 10 ng/ml rCCL18 stimulation for 3 days. Western blot assays showed that compared with the Scr/MDA-231 cells, the expression levels of N-cadherin and vimentin were distinctly lower and the expression of E-cadherin was higher in the SiAnxA2/MDA-231 cells with 10 ng/ml rCCL18 for 3 days (Fig. 4A, left panels). In AnxA2/MCF-7 cells, the
AnxA2 expression was downregulated, whereas levels of vimentin and N-cadherin were upregulated (Fig. 4A, right panels). Immunofluorescence staining of cells indicated the same results (Fig. 4B). Next, the nuclear expression of Snail was distinctly upregulated in the Scr/MDA-231 cells with 10 ng/ml CCL18 stimulation. To confirm that AnxA2, as an upstream regulator, plays a role in the Akt/GSK3β signaling pathway to detect the activation of AnxA2 with rCCL18 stimulation for 3 days. The results suggested that the phosphorylation of AnxA2 was reduced in the SiAkt/MDA-231 cells and MDA-MB-231 cells with LY294002 compared with the Scr/MDA-231 cells (Fig. 4E). These results suggest that the PI3K/Akt/GSK3β/Snail signaling pathway is pivotal for AnxA2 to promote CCL18-induced EMT in breast cancer cells.

Discussion

Various nonmalignant stromal cells in the tumor microenvironment play a pivotal role in tumor progression and metastasis (31). CCL18, which is derived from TAMs, is correlated with the invasion, migration, metastasis, and poor prognosis of patients with breast cancer (32,33). Decades of research have shown that upregulation of Annexin A2 (AnxA2) is involved in many malignant neoplasms, and is associated with the aggressive- ness of breast cancer cells (17,34-36). Furthermore, AnxA2 may also be a significant biomarker for breast cancer diagnosis and a potential target for breast cancer therapy (37,38). In the present study, pathological investigation of breast tissue specimens revealed that compared with adjacent non-tumor tissues, AnxA2 was highly regulated in breast cancer tissues, and AnxA2 was highly expressed in 65% of patients with distant metastases and in 32% of those with non-lymph node metastases. AnxA2 was upregulated in 68% of patients with lymph node metastases and in 32% of those with non-lymph node metastases. AnxA2 was highly expressed in most breast cancer patient tissues and plays a vital role in lymph node and distant metastases. These findings suggested that AnxA2 was highly expressed in most breast cancer patient tissues and plays a vital role in lymph node and distant metastases. In addition, AnxA2 was highly expressed in highly invasive human breast cancer cells. This finding indicated that AnxA2 contributes to the invasion of breast cancer cells. In animal experiments, AnxA2 enhanced the metastasis of human breast cancer cells to lungs of SCID mice with rCCL18 stimulation, which provides molecular evidence that AnxA2 is indispensable for CCL18-induced metastasis of human breast cancer cells in vivo. For tumors to metastasize and invade, neoplastic and endothelial cells must migrate into surrounding tissues (39). In addition, migration is highly associated with infiltration and chemotaxis (40,41).
Figure 4. AnxA2 promotes CCL18-induced EMT via the Akt/GSK3β signaling pathway. (A) Expression levels of an epithelial marker (E-cadherin), as well as mesenchymal markers (N-cadherin and vimentin) were assessed by western blot analysis in Scr/MDA-231, SiAnxA2/MDA-231, Con/MCF-7 and AnxA2/MCF-7 cells upon 10 ng/ml rCCL18 stimulation. β-actin was used as a loading control. (B) Fluorescence microscopic staining of E-cadherin, N-cadherin and vimentin (red) is indicated in the Scr/MDA-231, SiAnxA2/MDA-231, Con/MCF-7 and AnxA2/MCF-7 cells upon rCCL18 stimulation. Nuclear DNA was stained with DAPI (blue). Scale bar, 20 µm. (C) Nuclear expression level of Snail in CCL18-induced Scr/MDA231 and SiAnxA2/MDA-231 cells was examined by Western blot analysis. Nucleolin was used as a loading control. rCCL18, 10 ng/ml. (D) Expression levels of p-Akt (Ser473), p-Akt (Thr308), p-GSK3β and GSK3β in the Scr/MDA-231, SiAnxA2/MDA-231, Con/MCF-7 and AnxA2/MCF-7 cells upon rCCL18 stimulation was detected by western blot analysis. Akt or β-actin was used as a loading control. (E) CCL18-induced MDA-231 and MCF-7 cells were pretreated with LY294002 (20 µM) for 1 h. The expression levels of p-AnxA2 and AnxA2 in the Scr/MDA-231, SiAkt/MDA-231, MDA-231 + LY294002, Con/MCF-7, Akt/MCF-7 and MCF-7 + LY294002 cells were detected by western blot analysis. rCCL18, 10 ng/ml. Data were collected from a representative of at least three independent experiments.

Figure 5. AnxA2 enhances CCL18-induced lung colonization of human breast cancer cells. (A) Micrometastasis in mouse lungs were visualized by hematoxylin and eosin (H&E) staining. Scale bar, 200 µm. (B) Lung metastatic nodules were counted and plotted (n=10). *P<0.05 (two-way ANOVA).

CCL18, chemokine (C-C motif) ligand 18; AnxA2, Annexin A2.
that AnxA2 contributed to F-actin polymerization to mediate the extracellular matrix (ECM) is regulated by integrin utes to cell movement, and the firm adhesion of tumor cells to result in net cell-body movement (42). Our study demonstrated cells to migrate in response to a chemoattractant. Cell migra-
upon rCCL18 stimulation in the chemotaxis and scratch assays. The present study, upregulation of AnxA2 expression distinctly migration and invasion of breast cancer cells. Adhesion contrib-
cytoskeletal rearrangement, providing the driving force for
without CCL18 stimulation. Moreover, the expression levels of other transcriptional factors (Slug, Twist1, Zeb1 and Zeb2) were stable in the Scr/MDA-231 and SiNir1/MDA-231 cells with or without CCL18 stimulation. Akt contributes to invasion and metastasis, which is a predominant component of the PI3K pathway. Our results showed that AnxA2 depletion in breast cancer cells inhibited CCL18-induced Akt and GSK3β phosphorylation, whereas the expression of Akt and GSK3β was not altered. In addition, AnxA2 enhanced the stabilization of Snail, which is a crucial transcriptional factor of the PI3K/Akt/GSK3β/Snail signaling pathway. In this study, AnxA2 promoted CCL18-induced EMT through the stabilization of Snail via the PI3K/Akt/GSK3β/Snail signaling pathway.

In conclusion, our findings indicated that upregulation of AnxA2 promotes breast cancer cell invasion and metastasis. More importantly, we elucidated the molecular mechanism by which AnxA2, as a downstream molecule of CCL18 binding to Nir1, promotes the progression of breast cancer cell lines. Thus, our research suggests a novel mechanism for CCL18-induced breast cancer cell invasion and metastasis and indicates a valuable prognostic marker and novel therapeutic target for breast cancer.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Scientific Foundation of China (nos. 81672631, 81872163, 81072068, 81472365 and 81572578), The Young and Middle-Aged Scientists Research Awards Foundation of Shandong Province (2010BSB14050), the Foundation of Shandong Educational Committee (J14LK13), the Scientific Foundation of Shandong Province (ZR2014HM003 and ZR2015HM028) and the Shandong Province Outstanding Youth Scientist Foundation Plan (BS2013YY020).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

BZ conceived and designed the study. CZ, SZ, ZY, ZD and RW performed the experiments and collected and analyzed the data. CZ, SZ and BZ wrote the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

Patient samples were collected according to a protocol approved by the Institutional Review Board, and patients provided signed consent for use of their tissue specimens in the present study. The study protocol was reviewed and approved by the Weifang Medical University Ethics Committee (approval no. 045, 26-Feb-2016). The study protocol for the animal study was reviewed and also approved by Weifang Medical University Ethics Committee (approval no. 045, 26-Feb-2016).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References